Member Info for Toyin

bigpunt, I dont see that happening. Any company interested will want to see proof of sales first and by the time that happens we will be generating enough free cash to reinvest into more aggressive marketing.

Clio, that was a reply to the posts, you really are to nice. Read bigpunts posts again, they are condescending and argumentative. Like I said I tried to help as I always do, but don’t take the ****! I don’t give a toss about new blood, I’ve done my research and I’m confident in my position, if the share price drops it’s Christmas as far as I am concerned!

Clio, I think you are being unfair saying bigpunt has had unfriendly responses, have you read the thread from the beginning. Posters including myself have tried to point bigpunt in the right direction. I suggest you read bigpunts posts before you say the board has been unfriendly. I offered up some links to presentation and interviews and get told the board should offer more sophisticated insights. I suggest you have a word with yourself!

bigpunt, the answer to your question is in one of those unsophisticated videos.

bigpunt, I thought it better to start at ground level as you obviously have little grasp on any part of the business. Fyi, the youtube videos would give you very good information and foundation, so instead of trying to be clever, learn to walk before you run!

bigpunt, I tried to help and gave you the benefit of the doubt with my first reply. You are obviously a trouble maker or stupid. I shall let you decide.

bigpunt, yes you are missing pretty much everything pertinent. So much so that you claim the ceo's strength is his scientific technical expertise! Ironically he is quite good at sales & marketing I believe.

I think the easiest way in is to watch some youtube presentations

https://youtu.be/5s68895i_Ds
https://youtu.be/uT5I0DonCk8
https://youtu.be/oDl1HGDX-dU
https://youtu.be/yRQN4Ur88pw

Farris, That would be Croda, smart partnership ;-)

Anyway, just received this via email.

AxisBiotix
Based on the success of our AxisBiotix-Ps supplement, we are now looking to expand our range and introduce a topical cream to help support your sensitive skin condition.

Answer our 1-minute survey for our topical cream research and have a chance to win a £50 Amazon gift voucher and a 28-day supply of AxisBiotix-Ps!!

START THE SURVEY

Austin the £22k was for H1 up to the end of December. Jan-June is H2.

Half year consolidated results
Manchester, UK - 29 March 2022 - SkinBioTherapeutics plc (AIM: SBTX or the "Group") a life sciences company focused on skin health, announces its unaudited half year consolidated results for the six months to 31 December 2021.

H1 has been and gone Austin, I think you mean H2/FY

belgrano, my current batch is 08/2023, the ones I had in Nov 21 were 6/2023, so plenty of life in them.

Farris, I dont see a fundraise at these prices. As of 31/12 we had £3.1m cash + £412k Axis stock, so we wont need any cash for day to day running. The only thing we would need cash for would be an acquisition but I think SA has got enough on his plate at the moment.

It's all there if you put a bit of effort in. Why you would ask pseudo experts for clarification is beyond me.

From RNS 29/3/22

Strong progress with oral research programme and skin health and disease programme at the University of Manchester

Beyond AxisBiotix-Ps, the Group has a broad base of technologies and during the remainder of 2022, management is looking to Sederma's launch of SkinBiotix as a cosmetic ingredient, the outcomes from the oral programme with the University of Manchester and the resultant early engagement with potential commercial partners.

sjs, I dont believe blue biotechnology does relate, or have anything to do sbtx.

Letitrun, Cenkos note below

SkinBioTherapeutics has provided a business update covering its lead products, AxisBiotix-Ps and SkinBiotix. The second phase of the launch of AxisBiotix-Ps was initiated in February, with a direct-to-consumer strategy including the use of social media influencers with psoriasis who are using the product. While the impact of the second phase will take several weeks to assess, the board believes our revenue forecast of £1.2m remains achievable for FY22E. Croda continues to make progress with SkinBiotix, with final manufacturing scale up progressing and the company engaging with its VIP client base with regards to the product. We maintain out Buy recommendation.

It says “the board believes our revenue forecast of £1.2m remains achievable for FY22E.”

Get that “our revenue forecast” I never said the company had nothing to do with it, I said the company didn’t issue the forecast. Not difficult is it you tool!

Obviously some on here are a tad stupid, so I shall let you crack on in your playpen.

mol, you are a clown, you say I close a post, yet you sign off by saying bye, because you know you are wrong.

By your logic a forecast would have to be in an rns because its price sensitive. I cant make it any easier for you.

The offer is still there. Speak soon, or not.

mol, that's a Listing Rules pdf. Please supply me with a company rns that states the company has issued a forecast, and I shall leave you in peace.

mol, no they cannot, they can give guidance, but cannot issue a forecast, this is a fact.

I will discuss all day long with you, but dont imply I said something I didn't.

mol, I never said that the BOD was absolved of responsibility, I said a company cannot issue a forecast, that is a fact.
As soon as the board new they would miss the forecast they issued an rns, this is also a fact.

Stop making **** up you idiot!